A recent study published in Scientific Reports in February 2025, reveals that exosomes derived from adipose mesenchymal stem cells (AMSCs) may offer a promising new approach to treating skin fibrosis in systemic sclerosis (SSc), commonly known as scleroderma. 

SSc is a chronic autoimmune disease characterised by progressive fibrosis of the skin and internal organs, leading to significant morbidity. Current treatments have limited efficacy, especially in addressing skin fibrosis, which affects over 90% of SSc patients. 

The study, led by researchers from Fudan University in Shanghai, investigated whether exosomes – nano-sized vesicles secreted by AMSCs – could replicate the therapeutic effects of the stem cells themselves. In laboratory experiments, both direct and indirect co-cultures of AMSCs with skin fibroblasts from SSc patients resulted in reduced expression of fibrosis markers, including α-SMA, COL1A1, COL3A1, and TGF-β1. 

Further analysis demonstrated that exosomes isolated from AMSCs could be taken up by SSc fibroblasts and similarly inhibit the expression of these fibrosis-related genes and proteins. Notably, the exosomes appeared to exert their anti-fibrotic effects by inhibiting the TGF-β1/Smad3 signaling pathway, a key regulator of fibrosis. 

To validate these findings in vivo, the researchers employed a bleomycin-induced mouse model of skin fibrosis. Mice treated with either AMSCs or their derived exosomes showed significant reductions in skin thickness and collagen deposition compared to untreated controls. Western blot analyses confirmed decreased levels of fibrosis markers and suppression of the TGF-β1/Smad3 pathway in treated mice. 

The authors suggest that AMSC-derived exosomes could serve as a ‘cell-free’ therapeutic alternative to stem cell transplantation, potentially mitigating risks associated with cell-based therapies, such as immune rejection and tumorigenicity. They conclude that these exosomes may be ‘rising star candidates’ for the treatment of SSc skin fibrosis. 

While these findings are promising, the study acknowledges the need for further research to fully understand the mechanisms involved and to assess the long-term safety and efficacy of exosome-based therapies in clinical settings.